modulant biosciences

What modulant biosciences does

Modulant Biosciences is a private biotechnology company headquartered in Fishers, Indiana, that develops small-molecule therapeutics for infectious and chronic diseases in animals. Founded in 2023, the company operates a proprietary allosteric modulation platform that targets aberrant multiprotein complexes formed when viruses and xenobiotics hijack normal cellular assembly machinery, restoring cellular homeostasis rather than attacking pathogens directly. The pipeline comprises three core programs: Feline Therapeutics (led by the orally administered candidate MAV-104, with published safety, pharmacokinetics, and efficacy data in domestic shorthair cats for Feline Infectious Peritonitis), a Canine Oncology platform marketed as a "One Drug for All Cancers" approach, and Swine Health Solutions targeting Porcine Reproductive and Respiratory Syndrome. The company has also added EL-22 and EL-32, myostatin-engineered probiotics for muscle preservation in animal health, through a licensing arrangement.

The company's business model is asset-light and partnership-driven. Modulant generates revenue through licensing its proprietary technology and therapeutic candidates to established animal health companies, with a sublicensing revenue share on the EL-22/EL-32 program licensed globally to Northstrive Biosciences. A research partnership with NutriQuest supports PRRSv and swine disease work. The company is led by CEO and co-founder Thomas Campi; the rest of the leadership team, headcount, and capitalization are not disclosed. To date, no commercial revenue, funding rounds, or institutional investors have been disclosed in available sources.

Name

modulant biosciences

Legal name

Modulant Biosciences

Website

https://modulant.bio

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Short description

Modulant Biosciences is an Indiana-based biotech developing proprietary small-molecule allosteric modulators to treat infectious and chronic diseases in companion and livestock animals, including FIP, canine cancer, and PRRS, monetizing via licensing partnerships.

Ownership category

akta.pro rank

Product category

Veterinary Pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Livestock & Production Animal Therapeutics (Rx) (HLAMAEAB)

akta.pro secondary industries

Biologics & Immunotherapies (Non-vaccine) (HLAMAEAK), Non-Human Microbiome Therapeutics (veterinary/animal microbiome interventions) (HLAAAFAL), Veterinary Pharmacy, Vaccine & Biologics Services (AFAEANAK)

Keywords

• Animal health therapeutics
• Small molecule drugs
• Allosteric modulators
• Veterinary pharmaceuticals
• Infectious disease treatment

Headquarters

HQ city

Fishers

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Therapeutic Licensing and Development: Modulant Biosciences generates revenue through licensing its proprietary allosteric modulation technology and therapeutic candidates to partners in the animal health industry. The company grants exclusive global rights to develop and commercialize its probiotic and small molecule therapeutics, receiving sublicensing revenue shares.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Modulant Biosciences develops proprietary small-molecule allosteric modulators as therapeutics for previously untreatable infectious and chronic diseases in animals. The pipeline targets feline infectious diseases (FIP, FelV), canine cancers, and porcine reproductive and respiratory syndrome (PRRS), as well as myostatin-engineered probiotics (EL-22, EL-32) for muscle preservation in animal health. Revenue is generated through licensing of these therapeutic candidates and proprietary technology to animal health partners.

Product overview

Modulant Biosciences operates a proprietary allosteric modulation technology platform for developing first-in-class veterinary therapeutics. The portfolio consists of three core therapeutic programs: Feline Therapeutics (targeting FIP and FelV with MAV-104), Canine Oncology (a universal cancer treatment platform), and Swine Health Solutions (targeting PRRS). Additionally, EL-22 and EL-32 are myostatin-engineered probiotics licensed for muscle preservation applications in animal health. All programs leverage the company's unique approach of targeting host cellular functions to restore cellular homeostasis and prevent viral replication.

Differentiator

Problem solved

Functional benefit

Products and services

• MAV-104 (Feline Therapeutics Program) Orally administered small-molecule allosteric modulator candidate for treatment of Feline Infectious Peritonitis (FIP) and Feline Leukemia Virus (FelV) in domestic shorthair cats, addressing previously untreatable feline infectious diseases.
• Canine Oncology Platform ("One Drug for All Cancers") Therapeutic platform for treatment of multiple canine cancer types, targeting fundamental cellular mechanisms to restore homeostasis with a single therapeutic approach using allosteric modulators.
• Swine Health Solutions (PRRS Program) Novel therapeutic program against Porcine Reproductive and Respiratory Syndrome (PRRS) in swine, addressing a disease that causes billions in annual economic losses to the global livestock industry.
• EL-22 Myostatin-engineered probiotic for muscle preservation in animal health, with exclusive global rights licensed to Northstrive Biosciences for development and commercialization in veterinary applications.
• EL-32 Myostatin-engineered probiotic targeting muscle growth and yield enhancement in farmed animals, part of dual myostatin asset collaboration with Northstrive Biosciences.

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Northstrive BiosciencescoreOEM/ Whitelabel/ Licensing Partner · 13 May 2025Northstrive Biosciences signed a binding term sheet with Modulant Biosciences for a future licensing agreement on EL-22, granting Modulant exclusive global rights to develop and commercialize the probiotic for animal health. The license covers patents and applications, with Modulant paying a share of sublicensing revenues. In February 2026, the parties finalized a definitive license agreement for commercialization of EL-22 and EL-32, myostatin-engineered probiotics for muscle preservation in animal health.
• NutriQuestcoreStrategic or Co-development Partner · 11 March 2024NutriQuest and Modulant Biosciences announced a partnership to advance crucial PRRSv and swine disease research. This collaboration focuses on developing novel therapeutics against Porcine Reproductive and Respiratory Syndrome (PRRS), addressing a devastating disease that causes billions in annual economic losses to the global livestock industry.

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Zoetis: The largest dedicated animal health company globally, with a broad portfolio of pharmaceuticals, vaccines, and diagnostics across companion and livestock animals. Zoetis is the most relevant incumbent against which Modulant's pipeline would compete for veterinary prescribing share and licensing attention.
• Elanco Animal Health: Major animal health company developing and commercializing therapeutics and vaccines across companion and production animals. Elanco's broad pipeline and swine health presence make it a direct incumbent comparable to Modulant across FIP, oncology, and PRRS-adjacent indications.
• Boehringer Ingelheim Animal Health: One of the largest animal health players, with a particularly strong swine vaccines and therapeutics franchise (including for PRRS). Highly relevant incumbent comparable on Modulant's swine and livestock programs.
• Virbac: Global animal health pharmaceutical company with a broad portfolio spanning companion animal therapeutics, vaccines, and parasiticides. Comparable as a broad incumbent serving similar veterinary customer channels and species.
• Dechra Pharmaceuticals: Specialty animal health company focused on companion animal pharmaceuticals, including endocrinology, dermatology, and critical care. Comparable on Modulant's feline and canine specialty therapeutic programs and licensing activity.
• Phibro Animal Health: Animal health and nutrition company with significant livestock and aquaculture focus, including vaccines and performance products. Comparable to Modulant on the swine and livestock side, and as a likely licensing counterparty for production-animal assets.
• Ceva Santé Animale: Global animal health company with strong positions in swine vaccines (including PRRS), companion animal therapeutics, and poultry. Directly comparable to Modulant on PRRS, feline, and canine programs.
• IDEXX Laboratories: Dominant companion animal diagnostics company that also participates in veterinary practice software and water/livestock testing. Comparable as a high-margin animal health platform with deep veterinary channel relationships Modulant would need to access for any in-house commercialization.

Emerging players

• Anivive Lifesciences: Early-stage animal health biotech developing novel therapeutics including a long-acting feline injectable for FIP — directly comparable as a smaller, venture-backed competitor in the same feline infectious disease niche.
• Invetx: Animal health biotechnology company developing protein-based therapeutics for companion animals, with backing from major animal health strategics. Comparable as a similarly sized, platform-based veterinary biotech pursuing novel modalities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/modulantbio

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about modulant biosciences